Physician profile
Onyemaechi N Okolo-Taku
NPI 1609254788
$8,946.52
in general payments reported to CMS, 2019-2025
58 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $407 · 2021: $432 · 2022: $1,341 · 2023: $1,379 · 2024: $1,535 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,729 · Education: $68.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,729.12 |
| Education | $68.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $559.28 | 2022-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $532.52 | 2019-2025 | Xospata, Vyloy |
| Pfizer INC. | $499.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $490.07 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $445.19 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $420.77 | 2021-2025 | |
| Amgen INC. | $364.17 | 2019-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $361.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $355.61 | 2022-2025 | Opdualag, Opdivo, Reblozyl |
| Kite Pharma, INC. | $312.36 | 2019-2025 | Yescarta |
| Incyte Corporation | $303.64 | 2019-2023 | Monjuvi |
| Genzyme Corporation | $301.05 | 2019-2025 | |
| Seagen INC. | $300.86 | 2019-2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $288.97 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Biocon Biologics INC | $279.57 | 2025 | Ogivri |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyemaechi Okolo-Taku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.